12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GLPG0974: Phase I data

A double-blind, placebo-controlled, Belgian Phase I trial in 32 healthy volunteers showed that once- and twice-daily ascending-doses of oral GLPG0974 for 2 weeks were well tolerated and dose-dependently...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >